The estimated Net Worth of Gregory K Hinckley is at least 1.09 百万$ dollars as of 16 June 2021. Gregory Hinckley owns over 6,170 units of SI-BONE Inc stock worth over 1,094,401$ and over the last 21 years Gregory sold SIBN stock worth over 0$.
Gregory has made over 5 trades of the SI-BONE Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently Gregory exercised 6,170 units of SIBN stock worth 36,650$ on 16 June 2021.
The largest trade Gregory's ever made was exercising 50,250 units of SI-BONE Inc stock on 26 August 2014 worth over 548,730$. On average, Gregory trades about 3,433 units every 257 days since 2003. As of 16 June 2021 Gregory still owns at least 72,573 units of SI-BONE Inc stock.
You can see the complete history of Gregory Hinckley stock trades at the bottom of the page.
Gregory's mailing address filed with the SEC is C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA, CA, 95050.
Over the last 6 years, insiders at SI-BONE Inc have traded over 114,943,926$ worth of SI-BONE Inc stock and bought 1,250,000 units worth 18,750,000$ . The most active insiders traders include David P Bonita、Advisors Llc Orbi Med Capit...、John Gordon Freund. On average, SI-BONE Inc executives and independent directors trade stock every 8 days with the average trade being worth of 401,535$. The most recent stock trade was executed by Anshul Maheshwari on 3 September 2024, trading 1,414 units of SIBN stock currently worth 23,119$.
si-bone® is focused on helping patients in one of the most under-served, under-diagnosed, and under-treated areas in orthopedics, the sacroiliac (si) joint. si-bone developed an innovative, patented implant to fuse the si joint. the ifuse implant system® provides a less invasive alternative to traditional sacroiliac (si) joint fusion surgery and has been used in over 25,000 procedures to date. the company is managed by an experienced team of executives from kyphon, medtronic, inbone, saint francis and several start up orthopedic and spine companies. the ifuse implant system is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. this includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. there are potential risks associated with the ifuse implant system. it may not be appropriate for al
SI-BONE Inc executives and other stock owners filed with the SEC include: